Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ECI830 + ribociclib + fulvestrant
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
**ECI830 + ribociclib + fulvestrant** is a combination regimen under clinical investigation for the treatment of advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. ECI830 is a novel CDK2 inhibitor; ribociclib is a CDK4/6 inhibitor, and fulvestrant is an estrogen receptor antagonist. The combination targets the cell cycle and estrogen signaling: ECI830 inhibits cyclin-dependent kinase 2 (CDK2), ribociclib inhibits CDK4/6, and fulvestrant causes degradation and antagonism of estrogen receptor, collectively aiming to suppress tumor cell proliferation and overcome resistance to endocrine therapy. The regimen is being evaluated in phase I/II studies to assess safety, optimal dosing, and anti-tumor efficacy after progression on prior hormonal therapy and CDK4/6 inhibitor[1][3][4][7][10].
- Other names
- ECI830 + ribociclib + fulvestrant
02
Targets
ER (Estrogen receptor)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on ECI830 + ribociclib + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECI830 + ribociclib + fulvestrant.